Systemic Lupus Erythematosus

TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]

Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]

Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]

Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]

In women with systemic lupus erythematosus (SLE), ill-timed pregnancies can cause complications related to teratogen use and SLE activity. In this touchIMMUNOLOGY interview we spoke with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study implementing the HOP-STEP intervention to promote well-timed pregnancies in women with SLE, and the impact of the HOP-STEP […]

WILLOW is a phase II, double-blind study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus (NCT05162586). touchIMMUNOLOGY were delighted to speak with Dr. David R Pearson (University of Minnesota, Minneapolis, MN, USA) about the findings from preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran, and about the aims, eligibility criteria and primary and secondary outcome measures of the WILLOW study. The abstract 'Enpatoran: Preclinical Evidence Supporting Glucocorticoid Dose Reduction and Phase II Study Design in Patients with SLE and/or CLE (WILLOW).' (Abstract number: 1230) was presented at EADV 2022, 7-10 September, 2022. Questions Could you tell us a little about the preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran? (0:20) What were the findings of these studies? (1:23) What are the aims, design and eligibility criteria of the WILLOW study? (3:13) What are the primary and secondary outcome measures of the study? (3:44) Disclosures: David R Pearson discloses consulting for Biogen, Inc and receiving grant/ research support from Corbus, EMD Serono, Emerald Health, Kadmon, Pfizer, and Priovant. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.